Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2005.01.128 on December 21 2004

Journal of Clinical Oncology, Vol 23, No 4 (February 1), 2005: pp. 741-750
© 2005 American Society of Clinical Oncology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanderson, K.
Right arrow Articles by Weber, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanderson, K.
Right arrow Articles by Weber, J.
Related Articles
Right arrowRelated Editorials
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma

Kristin Sanderson, Ronald Scotland, Peter Lee, Dongxin Liu, Susan Groshen, Jolie Snively, Shirley Sian, Geoffrey Nichol, Thomas Davis, Tibor Keler, Michael Yellin, Jeffrey Weber

From the Departments of Medicine, Urology, and Preventive Medicine, Keck/University of Southern California School of Medicine, Los Angeles; Department of Medicine, Stanford University School of Medicine, Stanford, CA; and Medarex Inc, Bloomsbury, NJ

Address reprint requests to Jeffrey Weber, MD, PhD, Department of Medicine, Keck School of Medicine, University of Southern California/Norris Cancer Center, 1441 Eastlake Ave, Los Angeles, CA 90033; e-mail: jweber{at}usc.edu

PURPOSE: Nineteen patients with high-risk resected stage III and IV melanoma were immunized with three tumor antigen epitope peptides from gp100, MART-1, and tyrosinase emulsified with adjuvant Montanide ISA 51 and received a fully human anti-cytotoxic T-lymphocyte antigen-4 (anti–CTLA-4) monoclonal antibody MDX-010. Each of three cohorts received escalating doses of antibody with vaccine primarily to evaluate the toxicities and maximum-tolerated dose (MTD) of MDX-010 with vaccine. MDX-010 pharmacokinetics and immune responses were secondary end points.

PATIENTS AND METHODS: Peptide immunizations with MDX-010 were administered every 4 weeks for 6 months and then every 12 weeks for 6 months. A leukapheresis to obtain peripheral-blood mononuclear cells for immune analyses was performed before treatment and after the sixth vaccination. Patients were observed until relapse.

RESULTS: Grade 3 gastrointestinal (GI) toxicity (diarrhea or abdominal pain) was observed in three patients in the highest dose cohort and one in the middle dose cohort who seemed to be autoimmune. That defined the MTD with vaccine on this schedule at 1 mg/kg. Of eight patients with evidence of autoimmunity, three have experienced disease relapse. Of 11 patients without autoimmune symptoms, nine have experienced disease relapse. Significant immune responses were measured by tetramer and enzyme-linked immunospot assays against gp100 and MART-1.

CONCLUSION: Dose-related autoimmune adverse events, predominantly skin and GI toxicities, were reversible. Patients mounted an antigen-specific immune response to a peptide vaccine when combined with a human anti–CTLA-4 antibody.

Supported by a grant from the Food and Drug Administration's Orphan Drug Program (FD-001-01) and by a grant from Medarex Corp.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Editorials

  • CTLA-4 Blockade: Unveiling Immune Regulation
    Glenn Dranoff
    JCO 2005 23: 662-664 [Full Text]
  • CTLA-4 Blockade: Unveiling Immune Regulation
    Glenn Dranoff
    JCO 2005 23: 662-664 [Full Text]


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. Weber, J. A. Thompson, O. Hamid, D. Minor, A. Amin, I. Ron, R. Ridolfi, H. Assi, A. Maraveyas, D. Berman, et al.
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Clin. Cancer Res., September 1, 2009; 15(17): 5591 - 5598.
[Abstract] [Full Text] [PDF]

Home page
 NDT PlusHome page
E. C. Jolly, M. R. Clatworthy, C. Lawrence, P. D. Nathan, and K. Farrington
Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
NDT Plus, August 1, 2009; 2(4): 300 - 302.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Robert and F. Ghiringhelli
What Is the Role of Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma?
Oncologist, August 1, 2009; 14(8): 848 - 861.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. Schonfeld, G. Matschiner, L. Chatwell, S. Trentmann, H. Gille, M. Hulsmeyer, N. Brown, P. M. Kaye, S. Schlehuber, A. M. Hohlbaum, et al.
An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies
PNAS, May 19, 2009; 106(20): 8198 - 8203.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Klein, L. M. Ebert, T. Nicholaou, J. Browning, S. E. Russell, M. Zuber, H. M. Jackson, N. Dimopoulos, B. S. Tan, A. Hoos, et al.
Melan-A-specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4
Clin. Cancer Res., April 1, 2009; 15(7): 2507 - 2513.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Bashey, B. Medina, S. Corringham, M. Pasek, E. Carrier, L. Vrooman, I. Lowy, S. R. Solomon, L. E. Morris, H. K. Holland, et al.
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
Blood, February 12, 2009; 113(7): 1581 - 1588.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Fong, S. S. Kwek, S. O'Brien, B. Kavanagh, D. G. McNeel, V. Weinberg, A. M. Lin, J. Rosenberg, C. J. Ryan, B. I. Rini, et al.
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
Cancer Res., January 15, 2009; 69(2): 609 - 615.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Ribas, B. Comin-Anduix, J. S. Economou, T. R. Donahue, P. de la Rocha, L. F. Morris, J. Jalil, V. B. Dissette, I. P. Shintaku, J. A. Glaspy, et al.
Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
Clin. Cancer Res., January 1, 2009; 15(1): 390 - 399.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. S. Weber, S. O'Day, W. Urba, J. Powderly, G. Nichol, M. Yellin, J. Snively, and E. Hersh
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
J. Clin. Oncol., December 20, 2008; 26(36): 5950 - 5956.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
V. A. Trinh and J. Poust
Introduction
Am. J. Health Syst. Pharm., December 15, 2008; 65(24_Supplement_9): S1 - S2.
[Full Text] [PDF]

Home page
 JCOHome page
L. Fong and E. J. Small
Anti-Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
J. Clin. Oncol., November 10, 2008; 26(32): 5275 - 5283.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Weber
Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010)
Oncologist, October 1, 2008; 13(suppl_4): 16 - 25.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Kavanagh, S. O'Brien, D. Lee, Y. Hou, V. Weinberg, B. Rini, J. P. Allison, E. J. Small, and L. Fong
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion
Blood, August 15, 2008; 112(4): 1175 - 1183.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Nishikawa, T. Kato, M. Hirayama, Y. Orito, E. Sato, N. Harada, S. Gnjatic, L. J. Old, and H. Shiku
Regulatory T Cell-Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling
Cancer Res., July 15, 2008; 68(14): 5948 - 5954.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Sittler, J. Zhou, J. Park, N. K. Yuen, S. Sarantopoulos, J. Mollick, R. Salgia, A. Giobbie-Hurder, G. Dranoff, and F. S. Hodi
Concerted Potent Humoral Immune Responses to Autoantigens Are Associated with Tumor Destruction and Favorable Clinical Outcomes without Autoimmunity
Clin. Cancer Res., June 15, 2008; 14(12): 3896 - 3905.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Kline, I. E. Brown, Y.-Y. Zha, C. Blank, J. Strickler, H. Wouters, L. Zhang, and T. F. Gajewski
Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma
Clin. Cancer Res., May 15, 2008; 14(10): 3156 - 3167.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
F. S. Hodi, M. Butler, D. A. Oble, M. V. Seiden, F. G. Haluska, A. Kruse, S. MacRae, M. Nelson, C. Canning, I. Lowy, et al.
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
PNAS, February 26, 2008; 105(8): 3005 - 3010.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. G. Downey, J. A. Klapper, F. O. Smith, J. C. Yang, R. M. Sherry, R. E. Royal, U. S. Kammula, M. S. Hughes, T. E. Allen, C. L. Levy, et al.
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Clin. Cancer Res., November 15, 2007; 13(22): 6681 - 6688.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
R. M. Wong, R. R. Scotland, R. L. Lau, C. Wang, A. J. Korman, W. M. Kast, and J. S. Weber
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
Int. Immunol., October 1, 2007; 19(10): 1223 - 1234.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. S. Hodi
Cytotoxic T-Lymphocyte Associated Antigen-4
Clin. Cancer Res., September 15, 2007; 13(18): 5238 - 5242.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Zang and J. P. Allison
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
Clin. Cancer Res., September 15, 2007; 13(18): 5271 - 5279.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Tarhini, J. M. Kirkwood, W. E. Gooding, C. Cai, and S. S. Agarwala
Durable Complete Responses With High-Dose Bolus Interleukin-2 in Patients With Metastatic Melanoma Who Have Experienced Progression After Biochemotherapy
J. Clin. Oncol., September 1, 2007; 25(25): 3802 - 3807.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
V. A. Love, N. Grabie, P. Duramad, G. Stavrakis, A. Sharpe, and A. Lichtman
CTLA-4 Ablation and Interleukin-12 Driven Differentiation Synergistically Augment Cardiac Pathogenicity of Cytotoxic T Lymphocytes
Circ. Res., August 3, 2007; 101(3): 248 - 257.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. Weber
Review: Anti CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events
Oncologist, July 1, 2007; 12(7): 864 - 872.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Ribas, D. C. Hanson, D. A. Noe, R. Millham, D. J. Guyot, S. H. Bernstein, P. C. Canniff, A. Sharma, and J. Gomez-Navarro
Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer
Oncologist, July 1, 2007; 12(7): 873 - 883.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Margolin, M. B. Atkins, J. P. Dutcher, M. S. Ernstoff, J. W. Smith II, J. I. Clark, J. Baar, J. Sosman, J. Weber, C. Lathia, et al.
Phase I Trial of BAY 50-4798, an Interleukin-2-Specific Agonist in Advanced Melanoma and Renal Cancer
Clin. Cancer Res., June 1, 2007; 13(11): 3312 - 3319.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Zhang, R. E. Sadun, R. S. Arias, M. L. Flanagan, S. M. Sachsman, Y.-C. Nien, L. A. Khawli, P. Hu, and A. L. Epstein
Targeted and Untargeted CD137L Fusion Proteins for the Immunotherapy of Experimental Solid Tumors
Clin. Cancer Res., May 1, 2007; 13(9): 2758 - 2767.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Z. R. Yurkovetsky, J. M. Kirkwood, H. D. Edington, A. M. Marrangoni, L. Velikokhatnaya, M. T. Winans, E. Gorelik, and A. E. Lokshin
Multiplex Analysis of Serum Cytokines in Melanoma Patients Treated with Interferon-{alpha}2b
Clin. Cancer Res., April 15, 2007; 13(8): 2422 - 2428.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. J. Small, N. S. Tchekmedyian, B. I. Rini, L. Fong, I. Lowy, and J. P. Allison
A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
Clin. Cancer Res., March 15, 2007; 13(6): 1810 - 1815.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. O'Mahony, J. C. Morris, C. Quinn, W. Gao, W. H. Wilson, B. Gause, S. Pittaluga, S. Neelapu, M. Brown, T. A. Fleisher, et al.
A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy
Clin. Cancer Res., February 1, 2007; 13(3): 958 - 964.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Hryniewicz, A. Boasso, Y. Edghill-Smith, M. Vaccari, D. Fuchs, D. Venzon, J. Nacsa, M. R. Betts, W.-P. Tsai, J.-M. Heraud, et al.
CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques
Blood, December 1, 2006; 108(12): 3834 - 3842.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Read, R. Greenwald, A. Izcue, N. Robinson, D. Mandelbrot, L. Francisco, A. H. Sharpe, and F. Powrie
Blockade of CTLA-4 on CD4+CD25+ Regulatory T Cells Abrogates Their Function In Vivo
J. Immunol., October 1, 2006; 177(7): 4376 - 4383.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
L. Chin, L. A. Garraway, and D. E. Fisher
Malignant melanoma: genetics and therapeutics in the genomic era.
Genes & Dev., August 15, 2006; 20(16): 2149 - 2182.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Ishida, T. Ishii, A. Inagaki, H. Yano, H. Komatsu, S. Iida, H. Inagaki, and R. Ueda
Specific Recruitment of CC Chemokine Receptor 4-Positive Regulatory T Cells in Hodgkin Lymphoma Fosters Immune Privilege
Cancer Res., June 1, 2006; 66(11): 5716 - 5722.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. E. Beck, J. A. Blansfield, K. Q. Tran, A. L. Feldman, M. S. Hughes, R. E. Royal, U. S. Kammula, S. L. Topalian, R. M. Sherry, D. Kleiner, et al.
Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte-Associated Antigen 4
J. Clin. Oncol., May 20, 2006; 24(15): 2283 - 2289.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
S. Tartz, J. Kamanova, M. Simsova, P. Sebo, S. Bolte, V. Heussler, B. Fleischer, and T. Jacobs
Immunization with a Circumsporozoite Epitope Fused to Bordetella pertussis Adenylate Cyclase in Conjunction with Cytotoxic T-Lymphocyte-Associated Antigen 4 Blockade Confers Protection against Plasmodium berghei Liver-Stage Malaria
Infect. Immun., April 1, 2006; 74(4): 2277 - 2285.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. Keilholz, P. Martus, and C. Scheibenbogen
Immune monitoring of T-cell responses in cancer vaccine development.
Clin. Cancer Res., April 1, 2006; 12(7): 2346s - 2352s.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Gogas, J. Ioannovich, U. Dafni, C. Stavropoulou-Giokas, K. Frangia, D. Tsoutsos, P. Panagiotou, A. Polyzos, O. Papadopoulos, A. Stratigos, et al.
Prognostic Significance of Autoimmunity during Treatment of Melanoma with Interferon
N. Engl. J. Med., February 16, 2006; 354(7): 709 - 718.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
S. H. Jaber, E. W. Cowen, L. R. Haworth, S. L. Booher, D. M. Berman, S. A. Rosenberg, and S. T. Hwang
Skin Reactions in a Subset of Patients With Stage IV Melanoma Treated With Anti-Cytotoxic T-Lymphocyte Antigen 4 Monoclonal Antibody as a Single Agent.
Arch Dermatol, February 1, 2006; 142(2): 166 - 172.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Chong and D. Cunningham
Improving Long-Term Outcomes for Patients With Liver Metastases From Colorectal Cancer
J. Clin. Oncol., December 20, 2005; 23(36): 9063 - 9066.
[Full Text] [PDF]

Home page
 JCOHome page
D. Kapadia and L. Fong
CTLA-4 Blockade: Autoimmunity As Treatment
J. Clin. Oncol., December 10, 2005; 23(35): 8926 - 8928.
[Full Text] [PDF]

Home page
 JCOHome page
A. Ribas, L. H. Camacho, G. Lopez-Berestein, D. Pavlov, C. A. Bulanhagui, R. Millham, B. Comin-Anduix, J. M. Reuben, E. Seja, C. A. Parker, et al.
Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte-Associated Antigen 4 Monoclonal Antibody CP-675,206
J. Clin. Oncol., December 10, 2005; 23(35): 8968 - 8977.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. M. Luiten, E. W.M. Kueter, W. Mooi, M. P.W. Gallee, E. M. Rankin, W. R. Gerritsen, S. M. Clift, W. J. Nooijen, P. Weder, W. F. van de Kasteele, et al.
Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF-Transduced Tumor Cells in Metastatic Melanoma Patients
J. Clin. Oncol., December 10, 2005; 23(35): 8978 - 8991.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Kirkwood
Building Upon the Standard of Care in Adjuvant Therapy of High-Risk Melanoma
J. Clin. Oncol., December 1, 2005; 23(34): 8559 - 8563.
[Full Text] [PDF]

Home page
 JCOHome page
P. Attia, G. Q. Phan, A. V. Maker, M. R. Robinson, M. M. Quezado, J. C. Yang, R. M. Sherry, S. L. Topalian, U. S. Kammula, R. E. Royal, et al.
Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti-Cytotoxic T-Lymphocyte Antigen-4
J. Clin. Oncol., September 1, 2005; 23(25): 6043 - 6053.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Dranoff
CTLA-4 Blockade: Unveiling Immune Regulation
J. Clin. Oncol., February 1, 2005; 23(4): 662 - 664.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online